Cell Therapeutics Responding To Inquiry Into Trisenox Off-Label Promotions
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle, Wash. U.S. attorney's office is investigating marketing practices for CTI's leukemia agent. The company's recent 10-Q filing acknowledges that Trisenox is "largely" prescribed off-label and some instances of off-label promotions have "likely" occurred.
You may also be interested in...
Cephalon To Develop Oncology Franchise Following Acquisition Of CTI’s Trisenox
Cephalon will build a hematology franchise around the Trisenox acquisition; the company may add its Phase II tyrosine kinase inhibitor (CEP-701) and Salmedix’ lymphoma treatment Treanda when that acqusition closes. CTI is selling Trisenox to reinvest in its late-stage pipeline.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.